Naila Taguieva-Pioger

Naila Taguieva-Pioger is an accomplished professional in the fields of clinical development and medical affairs, currently serving as Senior Director at Novo Nordisk and Executive Medical Director at Cure 51. Naila's extensive experience includes roles such as Senior Global Medical Director in Oncology Medical Affairs at Servier and Senior Global Medical Affairs Director at Ipsen. Prior positions at Roche Pharmaceuticals encompassed Senior Medical Group Leader for Oncology and Cancer Immunology, along with leadership in international medical differentiation strategy and transplantation. Naila's career began at AstraZeneca, LFB HQ, and Bausch & Lomb HQ as Global International Clinical Development Lead. Naila holds a PhD from Lomonosov Moscow State University and an MD from the First Moscow State Medical University named after I.M. Sechenov, along with additional qualifications in medical statistics from Pierre and Marie Curie University.